Soligenix, Inc. (NASDAQ:SNGX) Short Interest Update

Soligenix, Inc. (NASDAQ:SNGX) was the recipient of a significant decrease in short interest during the month of February. As of February 15th, there was short interest totalling 106,400 shares, a decrease of 12.1% from the January 31st total of 121,000 shares. Approximately 4.2% of the company’s shares are sold short. Based on an average daily trading volume, of 220,800 shares, the days-to-cover ratio is currently 0.5 days.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Soligenix stock. Geode Capital Management LLC increased its position in Soligenix, Inc. (NASDAQ:SNGX) by 42.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 26,094 shares of the biopharmaceutical company’s stock after purchasing an additional 7,729 shares during the quarter. Geode Capital Management LLC owned approximately 1.04% of Soligenix worth $71,000 as of its most recent SEC filing. Institutional investors own 3.60% of the company’s stock.

Soligenix Stock Performance

SNGX opened at $2.33 on Friday. Soligenix has a one year low of $1.83 and a one year high of $14.92. The stock has a market cap of $5.85 million, a price-to-earnings ratio of -0.31 and a beta of 1.83. The stock’s 50 day moving average price is $2.54 and its 200-day moving average price is $3.26.

About Soligenix

Soligenix, Inc, a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease.